Showing results (21-30 of 61) with videos related to

Sort By:
Pageof 7
Anticancer Research|June 11, 2013
The role of trastuzumab in the management of salivary ductal carcinomasAnthony J Perissinotti, Matthew Lee Pierce, Makala B Pace, et al.
Critical Reviews in Oncology/Hematology|February 29, 2020
Contemporary treatment options for a classical disease: Advanced Hodgkin lymphomaJustin H Reid, Bernard L Marini, Victoria R Nachar, et al.
Open Forum Infectious Diseases|May 25, 2019
Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction ChemotherapyHeena P Patel, Anthony J Perissinotti, Twisha S Patel, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 2, 2021
Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort studyBrian G Bazzell, Bernard L Marini, Lydia L Benitez, et al.
The Journal of Antimicrobial Chemotherapy|November 2, 2017
Risk factors for subtherapeutic levels of posaconazole tabletLaura A Tang, Bernard L Marini, Lydia Benitez, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 24, 2021
Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell LymphomaBrian G Bazzell, Lydia L Benitez, Bernard L Marini, et al.
Leukemia & Lymphoma|November 20, 2019
Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosisJustin H Reid, Anthony J Perissinotti, Lydia Benitez, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 17, 2021
Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be FollowedMarcus J Geer, Charles E Foucar, Sumana Devata, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 22, 2021
Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid LeukemiaJustin H Reid, Bernard L Marini, Lydia L Benitez, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 13, 2019
Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOMLauren E Merz, Anthony J Perissinotti, Bernard L Marini, et al.
Pageof 7